Download PDFPDF
Concise report
Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Can patients with established RA stop TNF blocker therapy?
    • Paul Emery, Arthritis Research UK Professor of Rheumatology
    • Other Contributors:
      • Benazir Saleem, Maya Buch

    Dear Editor,

    We read with interest the above publication which we found to be very informative.
    The article presents the results of a systemic literature review of patients with established rheumatoid arthritis (RA) (>2 years disease duration) treated with stable and effective disease modifying anti-rheumatic drug (DMARD) therapy, with a metaanalysis to determine the effect of therapy withdrawal...

    Show More
    Conflict of Interest:
    None declared.